Li Shensui

Dr. Li Shensui


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Archives of Oral Biology
Verified
Journal Article
Closed access
LSLi Shensui
Li Shensui
XTXudong Tian
Xudong Tian
JSJukun Song
Jukun Song
YWYadong Wu
Yadong Wu
WWWeili Wang
Weili Wang
ZTZhenglong Tang
Zhenglong Tang

4 May 2026 in Archives of Oral Biology
Verified
Journal Article
Closed access
LSLi Shensui
Li Shensui
XTXudong Tian
Xudong Tian
JSJukun Song
Jukun Song
YWYa-Dong Wu
Ya-Dong Wu
WWWeili Wang
Weili Wang
ZTZhenglong Tang
Zhenglong Tang

1 June 2025
Verified
Journal Article
Closed access
LSLi Shensui
Li Shensui
XTXudong Tian
Xudong Tian
YWYadong Wu
Yadong Wu
WWWeili Wang
Weili Wang
ZTZhenglong Tang
Zhenglong Tang

7 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
LSLi Shensui
Li Shensui
WWWang Weili
Wang Weili
TXTian Xu-Dong
Tian Xu-Dong
LLLi Longjiang
Li Longjiang
HMHong Ma
Hong Ma
Objective:Aimed to evaluate the effect and response from the adjuvant chemotherapy for locally advanced oral squamous cell carcinoma. Methods: Retrospectively collected 46 patients with local late oral squamous cell carcinoma admitted from 2017 to 2021. The patients were treated with TPF induction chemotherapy. All patients completed at least 2 cycle of TPF (PF) regimen (75 mg / m2 of docetaxel on day 1 + 75 mg / M2 of cisplatin on day 1 + 750 mg / m2 of 5-fluorouracil on days 1 ~ 5, one cycle every 21 days), The primary end-points were overall response rate, safety of therapy and overall survival were evaluated. Results: After two cycles of TPF treatment, patients continued receiving surgery followed by radiotherapy or chemotherapy, include 5 patients were received PF. The complete remission rate was 6.25% (2/32), and the objective remission rate was 71.88% (23/32). Most of the adverse factors of chemotherapy response are alleviated. The median follow-up time was 26 months, and the median OS was 25.51 ± 3.81 months. Conclusion: Neoadjuvant chemotherapy, such as TPF or PF, plays an important role in the comprehensive treatment of advanced OSCC and postoperative assessments of white blood cell can provide high-quality prognostic information.